OncoVerity
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
OncoVerity, founded in 2022 in Aurora, Colorado and led by CEO Max Colao, is a biotechnology company developing targeted cancer therapies through a computational biology platform. It uses single-cell analysis and machine learning on a large acute myeloid leukemia (AML) patient database to advance cusatuzumab, a first-in-class monoclonal anti-CD70 antibody for AML, currently in a Phase 2 trial in combination with venetoclax and azacitidine.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Founded
OncoVerity was established in Aurora, Colorado, within the Fitzsimons Innovation Community, applying computational tools to clinical and biological data to develop targeted cancer therapies.
- Series A
OncoVerity raised a Series A round (completed March 2023) to advance its bioinformatics-driven drug development, with investors including argenx and RefinedScience.
- Series A extension
OncoVerity closed a $14 million Series A extension in December 2024, led by existing investors argenx and RefinedScience, to fund the Phase 2 OV-AML-1231 trial of cusatuzumab in newly diagnosed AML; patient enrollment was underway.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.